SPPAM
AMAG

Summit Partners Public Asset Management’s AMAG Pharmaceuticals AMAG Stock Holding History

Summit Partners Public Asset Management’s Portfolio AMAG Stock Details AMAG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-76,600
Closed -$3.04M – 73
2015
Q3 		$3.04M Sell
76,600
-23,400
-23% -$1.45M 1.15% 32
2015
Q2 		$6.91M Buy
+100,000
New +$6.29M 2.41% 12

Other funds holding AMAG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
SIM
Stelliam Investment Management New York $404M AUM 5.1% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Summit Partners Public Asset Management's AMAG Position: Q4 2015 in Review

Summit Partners Public Asset Management sold out of AMAG Pharmaceuticals (AMAG) in Q4 2015, closing a stake of 76,600 shares — an estimated $3.04M sold.

Summit Partners Public Asset Management first reported a position in AMAG in Q2 2015 and held it in 2 quarters. The position peaked at $6.91M in Q2 2015. 172 funds tracked by Wall St. Rank hold AMAG as of Q4 2015.

  • Summit Partners Public Asset Management reported no remaining AMAG Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
  • Summit Partners Public Asset Management sold 76,600 AMAG Pharmaceuticals shares in Q4 2015, an estimated $3.04M.
  • Summit Partners Public Asset Management first reported a position in AMAG Pharmaceuticals in Q2 2015 and held it in 2 quarters.
  • Summit Partners Public Asset Management's AMAG Pharmaceuticals position peaked at $6.91M in Q2 2015.
  • 172 funds tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q4 2015.

Based on Summit Partners Public Asset Management's 13F filing for Q4 2015, filed 16 Feb 2016.